Liraglutide to Improve corONary Haemodynamics During Exercise streSS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A single-centre double-blind placebo-controlled crossover randomised controlled trial to determine the physiological basis of glucagon-like peptide-1 receptor activation on exercise haemodynamics, as manifest through specific electrophysiological parameters measured by serial exercise stress testing, in those patients with reversible myocardial ischaemia and obstructive coronary artery disease confirmed by a baseline exercise test and coronary angiography respectively.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

NCT01179048

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE3

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

NCT01516255

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE1

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

NCT01800968

Acute Heart Failure

COMPLETED PHASE2

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

NCT01507311

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of LY3537021 in Healthy Participants

NCT05444569

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glucagon-like peptide-1 (GLP-1), an endogenous incretin hormone, is secreted by the gut in response to enteral nutrition and is responsible primarily for normal glucose homeostasis. There is a defective incretin effect in Type II diabetes mellitus such that meal-stimulated GLP-1 secretion is markedly impaired. However, a continuous infusion of exogenous GLP-1 can result in near normal insulin responses to a glucose load, suggesting preservation of insulinotropic activity. Liraglutide, a synthetic analogue that shares 97% structural homology to native GLP-1, is now a guideline-mandated antidiabetic therapy given as a once-daily subcutaneous injection.

Evidence emerging from animal and latterly human studies suggest GLP-1, independent of its effect on glycemic control and weight loss, may protect the heart from myocardial ischaemia/reperfusion injury and could potentially modulate the metabolic and haemodynamic outcomes of patients with coronary artery disease and left ventricular systolic dysfunction.

The investigators aim to determine whether chronic GLP-1 receptor occupancy has any effect on exercise haemodynamics in patients with known chronic stable angina, evidence of reversible ischaemia on exercise stress testing and angiographic evidence of obstructive coronary artery disease. Each study participant will be randomised to enter either a GLP-1 treatment arm or volume-matched saline placebo arm. Those randomised to GLP-1 will have a week's run-in phase with 0.6 mg Liraglutide followed by a week's course of 1.2 mg Liraglutide. At the end of Week 2, patients in the treatment arm will have their first exercise tolerance test (ETT). They will then be up-titrated to high dose 1.8 mg Liraglutide for another week before performing a Week 3 ETT. Patients in the placebo arm will have matched volume saline injections for the first two weeks before the Week 2 ETT and then another week of saline injections before the Week 3 ETT.

At the end of Week 3 patients will crossover so that those in the GLP-1 treatment arm cross to the placebo arm and vice versa. By incorporating a run-in phase followed by a step-wise increase in Liraglutide therapy over a 3-week period the investigators aim to minimise the occurrence of adverse reactions and also hope to observe a dose-response effect on exercise haemodynamics. The crossover design will allow study participants to effectively act as their own controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischaemic Heart Disease Coronary Heart Disease Chronic Stable Angina

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liraglutide

Week 1 Run-In Phase = 0.6 mg (0.1 ml) Liraglutide once daily via subcutaneous injection

Week 2 Low-Dose Phase = 1.2 mg (0.2 ml) Liraglutide once daily via subcutaneous injection

Week 3 High-Dose Phase = 1.8 mg (0.3 ml) Liraglutide once daily via subcutaneous injection

Group Type ACTIVE_COMPARATOR

Liraglutide

Intervention Type DRUG

GLP-1 receptor agonist administered via subcutaneous injection

Saline Placebo

Week 1 Run-In Phase = 0.1 ml normal saline once daily via subcutaneous injection

Week 2 Low-Dose Phase = 0.2 ml normal saline once daily via subcutaneous injection

Week 3 High-Dose Phase = 0.3 ml normal saline once daily via subcutaneous injection

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Volume-matched normal saline placebo administered via subcutaneous injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liraglutide

GLP-1 receptor agonist administered via subcutaneous injection

Intervention Type DRUG

Placebo

Volume-matched normal saline placebo administered via subcutaneous injection

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Victoza

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women aged 18-80
2. Patients with a recent abnormal exercise tolerance test demonstrating \>0.1 mV of planar or down-sloping ST-segment depression.
3. Patients with known coronary artery disease and angiographic evidence of a \>70% stenosis in a main epicardial artery, with or without coronary stenoses elsewhere.
4. Patients must be able to walk confidently on a treadmill.
5. Patients must have a normal resting electrocardiogram (ECG) in sinus rhythm without bundle branch aberration or other conduction disturbance.
6. Patients must have normal left ventricular function.

Exclusion Criteria

1. An abnormal resting ECG including atrial fibrillation, bundle branch aberration or other conduction disturbance.
2. Pre-existing left ventricular systolic dysfunction.
3. Pre-existing ischaemic or non-ischaemic cardiomyopathy.
4. Pre-existing valvular heart disease.
5. Inability to safely negotiate an exercise treadmill.
6. Type I diabetes mellitus.
7. Type II diabetes mellitus taking oral or subcutaneous anti diabetic therapy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No